^
Association details:
| Biomarker: | HER-2 A775_G776insYVMA |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tarlox (tarloxotinib bromide) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes
Published date:
12/22/2020
Excerpt:
Finally, a patient with lung adenocarcinoma harboring a HER2 exon 20 p.A775_G776insYVMA mutation demonstrated a dramatic clinical response to tarloxotinib.
DOI:
10.1158/1078-0432.CCR-20-3555
